Avexitide's pivotal Phase 3 readout in post-bariatric hypoglycemia is the single event that determines whether Amylyx's cash-rich rebuild produces an approved drug or a preclinical holding company

Bull

A positive LUCIDITY readout would show avexitide achieving statistically significant and clinically meaningful reduction in hypoglycemic episodes versus placebo across the 16-week double-blind period, with a clean safety profile consistent with prior trials. This would enable an NDA submission in 2027, validate the cash-rich rebuild thesis, and establish Amylyx as the first company to bring an approved pharmacotherapy specifically indicated for post-bariatric hypoglycemia — a condition with no currently approved drug options — unlocking a highly differentiated commercial opportunity in a rare, underserved population.

Bear

A negative outcome would most likely manifest as failure to achieve statistical significance on the primary hypoglycemia endpoint, potentially driven by high placebo response in this subjective, lifestyle-sensitive population or insufficient effect size in the relatively small 78-patient trial. A secondary failure mode would be an unexpected safety signal — gastrointestinal intolerance or cardiovascular findings — that complicates the benefit-risk profile even if efficacy trends are present; either scenario would strand the company as a preclinical holding company dependent on early-stage programs with no near-term approval pathway.